Somekawa Layla, Maegawa Hikoichiro, Tsukada Shinsuke, Nakamura Takatoshi
Office of OTC/Quasi-drugs, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
Office of Vaccines and Blood Products, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
J Intercult Ethnopharmacol. 2017 Jul 16;6(3):333-338. doi: 10.5455/jice.20170713091550. eCollection 2017 Jul-Sep.
Currently, there are no standardized regulatory systems for herbal medicinal products worldwide. Communication and sharing of knowledge between different regulatory systems will lead to mutual understanding and might help identify topics which deserve further discussion in the establishment of common standards. Regulatory information on traditional herbal medicinal products in Japan is updated by the establishment of Application Guidance for over-the-counter non-Kampo Crude Drug Extract Products. We would like to report on updated regulatory information on the new Application Guidance. Methods for comparison of Crude Drug Extract formulation and standard decoction and criteria for application and the key points to consider for each criterion are indicated in the guidance. Establishment of the guidance contributes to improvements in public health. We hope that the regulatory information about traditional herbal medicinal products in Japan will be of contribution to tackling the challenging task of regulating traditional herbal products worldwide.
目前,全球范围内尚无针对草药产品的标准化监管体系。不同监管体系之间的知识交流与共享将促进相互理解,并可能有助于确定在制定共同标准时值得进一步讨论的议题。日本通过制定非汉方药生药提取物产品的非处方药应用指南,更新了传统草药产品的监管信息。我们将汇报新应用指南中更新的监管信息。该指南指明了生药提取物配方与标准汤剂的比较方法、应用标准以及各项标准需考虑的要点。该指南的制定有助于公共卫生的改善。我们希望日本传统草药产品的监管信息将有助于应对全球范围内传统草药产品监管这一具有挑战性的任务。